Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.82 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.82 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.82 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.48 |
| ▸ | WIZ | O95785 | 2/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420536 | 1.00 | CRBN (0.82) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL26619550 | 0.92 | CRBN (0.82) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL17420664 | 0.91 | CRBN (0.86) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL19116289 | 0.91 | CRBN (0.86) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL31729618 | 0.91 | CRBN (0.86) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL17420533 | 0.90 | CRBN (0.85) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL29357669 | 0.90 | CRBN (0.85) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL17420574 | 0.90 | CRBN (0.85) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL17420597 | 0.90 | CRBN (0.85) | CRBNGSPT1DDB1CYP2C19KCNH2 | |
| SCHEMBL29374520 | 0.90 | CRBN (0.85) | CRBNGSPT1DDB1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | CRBN 1468/4885GSPT1 2184/4885DDB1 629/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | CRBN 1468/4885GSPT1 2184/4885DDB1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.